Functional effects of chronic paroxetine versus placebo on the fear, stress and anxiety brain circuit in Social Anxiety Disorder: Initial validation of an imaging protocol for drug discovery

European Neuropsychopharmacology

Volumn 24, Issue 1, 2014, Pages 105-116

  Giménez, Mónica ^a   Ortiz, Hector ^a   Soriano Mas, Carles ^b   López Solà, Marina ^a,b   Farré, Magí ^a,c   Deus, Joan ^a,c   Martín Santos, Rocio ^a,d   Fernandes, Sofia ^e   Fina, Paolo ^e   Bani, Massimo ^e   Zancan, Stefano ^e   Pujol, Jesús ^a   Merlo Pich, Emilio ^e,f  

^a HOSPITAL DEL MAR   (Spain)

^b HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e GSK   (Italy)

^f pRED NORD DTA Hoffmann La Roche   (Switzerland)

Author keywords

Anxiety; FMRI; Placebo; Public speaking test; Randomized clinical trial; Resting state; Social emotional stimuli

Indexed keywords

PAROXETINE; PLACEBO;

ADULT; AMYGDALOID NUCLEUS; ANTERIOR CINGULATE; ANXIETY; ANXIETY DISORDER; ARTICLE; BRAIN FUNCTION; CLINICAL ARTICLE; CLINICAL GLOBAL INVENTORY-IMPROVEMENT; CONTROLLED STUDY; DISTRESS SYNDROME; DIZZINESS; DRUG DEVELOPMENT; DRUG EFFECT; FEAR; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; INDEPENDENT COMPONENT ANALYSIS; INSULA; LIEBOWITZ SOCIAL ANXIETY SCALE; MALE; NAUSEA; NEUROIMAGING; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; PUBLIC SPEAKING; RANDOMIZED CONTROLLED TRIAL; SOCIAL PHOBIA; SOMNOLENCE; STRESS; TASK PERFORMANCE; THALAMUS; YOUNG ADULT;

ANXIETY; FMRI; PLACEBO; PUBLIC SPEAKING TEST; RANDOMIZED CLINICAL TRIAL; RESTING STATE; SOCIAL EMOTIONAL STIMULI;

ADULT; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANXIETY; BRAIN; BRAIN MAPPING; FEAR; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MOTOR ACTIVITY; PAROXETINE; PHOBIC DISORDERS; SPEECH; STRESS, PSYCHOLOGICAL; TIME FACTORS; VISUAL ANALOG SCALE; VISUAL PERCEPTION; YOUNG ADULT;

EID: 84892480239     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2013.09.004     Document Type: Article

References (51)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR 2000, American Psychiatric Press, Washington, (Text revision). fourth ed.
2. Aupperle R.L., Ravindran L., Tankersley D., Flagan T., Stein N.R., Simmons A.N., Stein M.B., Paulus M.P Pregabalin influences insula and amygdala activation during anticipation of emotional images. Neuropsychopharmacology 2011, 36:1466-1477.
3. Blair K.S., Geraci M., Otero M., Majestic C., Odenheimer S., Jacobs M., Blair R.J., Pine D.S. Atypical modulation of medial prefrontal cortex to self-referential comments in generalized social phobia. Psychiatry Res. 2011, 193:38-45.
4. Britton J.C., Stewart E., Killgore W.D.S., Rosso I.M., Price L.M., Gold A.L., Pine D.S., Wilhelm S., Jenike M.A., Rauch S.L. Amygdala activation in response to facial expressions in pediatric obsessive-compulsive disorder. Depr. Anx. 2010, 27:643-651.
5. Cardoso de Almeida J.R., Kronhaus D.M., Sibille E.L., Langenecker S.A., Versace A., LaBarbara E.J., Phillips M.L. Abnormal left-sided orbitomedial prefrontal cortical-amygdala connectivity during happy and fear face processing: a potential neural mechanism of female MDD. Front. Psychiatry 2010, 10.3389/fpsyt.2011.00069.
6. Clauss J.A., Cowan R.L., Blackford J.U. Expectation and temperament moderate amygdala and dorsal anterior cingulate cortex responses to fear faces. Cogn. Affect. Behav. Neurosci. 2011, 11:13-21.
7. Cooney R.E., Atlas L.Y., Joormann J., Eugène F., Gotlib I.H. Amygdala activation in the processing of neutral faces in social anxiety disorder: is neutral really neutral?. Psychiatry Res. Neuroimaging 2006, 148:55-59.
8. Etkin A., Egner T., Peraza D.M., Kandel E.R., Hirsch J. Resolving emotional conflict: a role for the rostral anterior cingulate cortex in modulating activity in the amygdala. Neuron 2006, 51:871-882.
9. Etkin A., Wager T.D. Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder and specific phobia. Am. J. Psychiatry 2007, 164:1476-1488.
10. Findling R.L., Nucci G., Piergies A.A., Gomeni R., Bartolic E.I., Fong R., Carpenter D.J., Leeder J.S., Gaedigk A., Danoff T.M. Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder. Neuropsychopharmacology 2006, 31:1274-1285.
11. Fox M.D., Raichle M.E. Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging. Nat. Rev. Neurosci. 2007, 8:700-711.
12. Fu C.H.Y., Williams S.C.R., Brammer M.J., Suckling J., Kim J., Cleare A.J., Walsh N.D., Mitterschiffthaler M.T., Andrew C.M., Merlo Pich E., Bullmore E.T. Attenuation of the neural response to sad faces in major depression by antidepressant treatment: a prospective, event-related functional magnetic resonance imaging study. Arch. Gen. Psychiatry 2004, 61:877-889.
13. Furmark T., Appel L., Michelgård A., Wahlstedt K., Åhs F., Zancan S., Jacobsson E., Flyckt K., Bergström M., Merlo Pich E., Nilsson M., Bani M., Långström B., Fredrikson M. Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol. Psychiatry 2005, 58:132-142.
14. Furmark T., Henningsson S., Appel L., Ahs F., Linnman C., Pissiota A., Faria V., Oreland L., Bani M., Merlo-Pich E., Eriksson E., Fredrikson M. Genotype over diagnosis in amygdala responsiveness: affective processing in social anxiety disorder. J. Psychiatry Neurosci. 2009, 34:30-40.
15. Giménez M., Pujol J., Ortiz H., Soriano-Mas C., López-Solà M., Farré M., Deus J., Merlo-Pich E., Martín-Santos R. Altered brain functional connectivity in relation to perception of scrutiny in social anxiety disorder. Psychiatry Res. 2012, 202:214-223.
16. Godlewska B., Norbury R., Selveraj S., Cowen P. Decreased neural response to fear after a short-term SSRI treatment: A 3T functional magnetic resonance imaging study. Eur. Neuropsychopharm 2011, 21(Suppl 1):S73.
17. Goldin P.R., Manber T., Hakimi S., Canli T., Gross J.J. Neural bases of social anxiety disorder: emotional reactivity and cognitive regulation during social and physical threat. Arch. Gen. Psychiatry 2009, 66:170-180.
18. Graeff F.G., Del-Ben C.M., Guimarães F.S. Pharmacology of human experimental anxiety. Brazilian J. Med. Biol. Res. 2003, 36(4):421-432.
19. Hariri A.R., Tessitore A., Mattay V.S., Fera F., Weinberger D.R The amygdala response to emotional stimuli: a comparison of faces and scenes. Neuroimage 2002, 17:317-323.
20. Harmer C.J., Mackay C.E., Reid C.B., Cowen P.J., Goodwin G.M. Antidepressant drug treatment modifies the neural processing of nonconscious threat cues. Biol. Psychiatry 2006, 59:816-820.
21. Harrison B.J., Soriano-Mas C., Pujol J., Ortiz H., López-Solà M., Hernández-Ribas R., Deus J., Alonso P., Yücel M., Pantelis C., Menchón J.M., Cardoner N. Altered corticostriatal functional connectivity in obsessive-compulsive disorder. Arch. Gen. Psychiatry 2009, 66:1189-1200.
22. Hedges D.W., Brown B.L., Shwalb D.A. A direct comparison of effect sizes from the clinical global impression- improvement scale to effect sizes from other rating scales in controlled trials of adult social anxiety disorder. Hum. Psychopharmacol. 2009, 24(1):35-40.
23. Henseler I., Krüger S., Dechent P., Gruber O. A gateway system in rostral PFC? Evidence from biasing attention to perceptual information and internal representations. Neuroimage 2011, 56:1666-1676.
24. Kumar P., Fillipini N., Fisher M., Lees J., DiSimplicio M., Dourish C.T., Dawson G.R., Craig K.J., Williams S.C., Deakin J.F.W., Goodwin G.M., Harmer C.J. A week of escitalopram decreases default mode network activity in dysphoric and non-dysphoric participants. Biol. Psychiatry 2012, 71:8(SUPPL. 1):199S.
25. Lees J., McKie S., Dadhiwala R., Horgan P., Dawson G., Seguin L., Mocaër E., Deakin J.F.W. Effect of a single dose (50mg) of agomelatine on bold fMRI responses to face emotion recognition in healthy volunteers. Eur. Neuropsychopharmacology 2010, 20(SUPPL. 3):S383-S384.
26. Li Y.O., Adali T., Calhoun V.D. Estimating the number of independent components for functional magnetic resonance imaging data. Hum. Brain Map 2007, 28:1251-1266.
27. Liebowitz M.R. Social phobia. Mod. Probl. Pharmacopsychiatry. 1987, 22:141-173.
28. Lorberbaum J.P., Kose S., Johnson M.R., Arana G.W., Sullivan L.K., Hamner M.B., Ballenger J.C., Lydiard R.B., Brodrick P.S., Bohning D.E., George M.S. Neural correlates of speech anticipatory anxiety in generalized social phobia. Neuroreport 2004, 15:2701-2705.
29. Marsh A.A., Finger E.C., Mitchell D.G.V, Reid A.E., Sims C., Kosson D.S., Towbin K.E., Liebenflut E., Pine D.S., Blair R.J.R Reduced amygdala response to fearful expression in children an adolescent with callous-unemotional trait and disruptive behavior disorders. Am J Psychiatry 2008, 165:712-720.
30. McCabe C., Mishor Z., Filippini N., Cowen P.J., Taylor M.J., Harmer C.J. SSRI administration reduces resting state functional connectivity in dorso-medial prefrontal cortex. Mol. Psychiatry 2011, 16(6):592-594.
31. MerloPich E. Understanding pharmacology in humans: PhaseI/PhaseII (Data Generation). Current Opinion in Pharmacology 2011, 11:557-562.
32. Northoff G., Heinzel A., de Greck M., Bermpohl F., Dobrowolny H., Panksepp J. Self-referential processing in our brain - a meta-analysis of imaging studies on the self. Neuroimage 2006, 31:440-457.
33. Paulus M.P., Stein M.B An insular view of anxiety. Biol. Psychiatry 2006, 60(4):383-387.
34. Paulus M.P., Feinstein J.S., Castillo G., Simmons A.N., Stein M.B. Dose-dependent decrease of activation in bilateral amygdala and insula by lorazepam during emotion processing. Arch. Gen. Psychiatry 2005, 62:282-288.
35. Phan K.L., Fitzgerald D.A., Nathan P.J., Tancer M.E. Association between amygdala hyperactivity to harsh faces and severity of social anxiety in generalized social phobia. Biol. Psychiatry 2006, 59:424-429.
36. Phan K.L., Orlichenko A., Boyd E., Angstadt M., Coccaro E.F., Liberzon I., Arfanakis K. Preliminary evidence of white matter abnormality in the uncinate fasciculus in generalized social anxiety disorder. Biol. Psychiatry 2009, 66(7):691-694.
37. Pujol J., Giménez M., Ortiz H., Soriano-Mas C., López-Solà M., Farré M., Deus J., Merlo-Pich E., Harrison B.J., Cardoner N., Navinés R., Martín-Santos R. Neural response to the observable self in social anxiety disorder. Psychol. Med. 2013, 43(4):721-731.
38. Pujol J., Harrison B.J., Ortiz H., Deus J., Soriano-Mas C., López-Solà M., Yücel M., Perich X., Cardoner N. Influence of the fusiform gyrus on amygdala response to emotional faces in the non-clinical range of social anxiety. Psychol. Med. 2009, 39:1177-1187.
39. Schneier F.R., Pomplun M., Sy M., Hirsch J. Neural response to eye contact and paroxetine treatment in generalized social anxiety disorder. Psychiatry Res. 2011, 194:271-278.
40. Shin L.M., Liberzon I. The neurocircuitry of fear, stress, and anxiety disorders. Neuropsychopharmacol 2010, 35:169-191.
41. Simmons A.N., Arce E., Lovero K.L, Stein M.B., Paulus M.P. Subchronic SSRI administration reduces insula response during affective anticipation in healthy volunteers. Int. J. Neuropsychopharmacol 2009, 12:1009-1020.
42. Spielberger C.D., Gorsuch R.L., Lushene R.E., Vagg P.R., Jacobs G.A. Manual for the State-trait Anxiety Inventory 1983, Consulting Psychologists Press, Palo Alto.
43. Spitzer R.L., Kroenke K., Williams J.B.W. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. JAMA. 1999, 282:1737-1744.
44. Tendolkar I., Van Wingen G., Urner M., Jan Verkes R., Fernández G. Short-term duloxetine administration affects neural correlates of mood-congruent memory. Neuropsychopharmacology 2011, 36:2266-2275.
45. Thomas K.M., Drevets W.C., Dahl R.E., Ryan N.D., Birmaher B., Eccard C.H., Axelson D., Whalen P.J., Casey B.J. Amygdala response to fearful faces in anxious and depressed children. Arch. Gen. Psychiatry 2001, 58(11):1057-1063.
46. Tromp D.P.M., Grupe D.W., Oathes D.J., McFarlin D.R., Hernandez P.J., Kral T.R.A., Lee J.E., Adams M., Alexander A.L., Nitschke J.B. Reduced structural connectivity of a major frontolimbic pathway in generalized anxiety disorder. Arch. Gen. Psychiatry 2012, 69(9):925-934.
47. Valenzuela M., Bartrés-Faz D., Beg F., Fornito A., Merlo-Pich E., Müller U., Öngür D., Toga A.W., Yücel M. Neuroimaging as endpoints in clinical trials: perspective from the first provence workshop. Mol. Psychiatry 2011, 16:1064.
48. Whalen P.J., Johnstone T., Somerville L.H., Nitschke J.B., Polis S., Alexander A.L., Davidson R.J., Kalin N.H A functional Magnetic Resonance Imaging predictor of treatment response to velanfaxine in Generalized Anxiety Disorder. Biol. Psychiatry 2008, 63(9):858-863.
49. Wagner K.D., Berard R., Stein M.B., Wetherhold E., Carpenter D.J., Perera P., Gee M., Davy K., Machin A. A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch. Gen. Psychiatry 2004, 61:1153-1162.
50. Wittchen H.U., Jacobi F., Rehm J., Gustavsson A., Swensson M., Jonsson B., Olesen J., Allulander C., Alonso J., Faravelli C., Fratiglioni L., Jennum P., Lieb R., Maercker A., van Os J., Preising M., Salvador-Carulla L., Simon R., Steinhausen H.C., et al. The size and burden of mental disorder and other disorder of the brain in Europe 2010. Eur. Neuropsychopharmacol 2011, 21:655-679.
51. Wollweber B.T., Kiem S.A., Hoehn D., Andrade K., Spoormaker V., Holsboer F., Czisch M., Sämann P.G. Effects of intravenous lorazepam on EEG power spectrum and fMRI functional connectivity. Eur. Arch. Psychiatry Clin. Neurosci. 2010, 260(Suppl. 1):S40.